External validation of the SOX-PTS score in a prospective multicenter trial of patients with proximal deep vein thrombosis by Rabinovich, Anat et al.
Washington University School of Medicine 
Digital Commons@Becker 
ICTS Faculty Publications Institute of Clinical and Translational Sciences 
2020 
External validation of the SOX-PTS score in a prospective 





Samuel Z. Goldhaber 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/icts_facpubs 
Authors 
Anat Rabinovich, Chu-Shu Gu, Suresh Vedantham, Clive Kearon, Samuel Z. Goldhaber, Heather L. Gornik, 
and Susan R. Kahn 
This is the peer reviewed version of the following article: 
Rabinovich A, Gu CS, Vedantham S, Kearon C, Goldhaber SZ, Gornik HL, Kahn SR; ATTRACT Trial 
Investigators. External validation of the SOX-PTS score in a prospective multicenter trial of patients 
with proximal deep vein thrombosis. J Thromb Haemost. 2020 Jun;18(6):1381-1389. 
which has been published in final form at https://doi.org/10.1111/jth.14791 
This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions 
for Use of Self-Archived Versions.
1
External validation of the SOX-PTS score (clinical prediction model for the post-
thrombotic syndrome) in a prospective multicenter trial of patients with proximal deep 
vein thrombosis  
Running head: External validation of the SOX-PTS score 
Anat Rabinovich*, Chu-Shu Gu†, Suresh Vedantham‡, Clive Kearon§, Samuel Z. 
Goldhaber¶, Heather L.Gornik** and Susan R. Kahn†† for the ATTRACT Trial Investigators 
*Thrombosis and Hemostasis unit, Hematology institute, Soroka University Medical Center,
Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel 
† Department of Oncology, McMaster University, Hamilton, ON, Canada 
‡ Mallinckrodt Institute of Radiology, Washington University in St. Louis, MO, USA 
§ Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON,
Canada 
¶ Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Harvard 
Medical School, Boston, MA, USA 
**University Hospitals, Case Western Reserve University, Cleveland Ohio, USA 
†† Jewish General Hospital, Lady Davis Institute, Center for Clinical Epidemiology, 
Montreal, QC, Canada 
Corresponding author: Anat Rabinovich, MD, Hematology Department, Soroka University 








Using data from the SOX Trial, we recently developed a clinical prediction model for 
occurrence of the post-thrombotic syndrome (PTS) after proximal deep vein thrombosis 
(DVT), termed the SOX-PTS score. The score includes anatomical extent of DVT; body 
mass index; and baseline Villalta score. 
 
Objective 
To externally validate the SOX-PTS score. 
 
Methods 
Logistic regression analysis of data from the ATTRACT Trial which evaluated 
pharmacomechanical catheter directed thrombolysis in patients with proximal DVT. The 
primary outcome was the occurrence of PTS (defined as Villalta score ≥ 5) from 6 to 24 
months after DVT. Secondary outcomes included moderate-severe PTS (Villalta scale ≥ 10) 
and severe PTS (Villalta scale ≥ 14). Predictive performance was assessed by discrimination 
and calibration. An updated score was evaluated in an exploratory analysis. 
 
Results 
691 ATTRACT patients were included, of whom 328 (47%) developed PTS. The c-statistic 
was 0.63; 95% confidence interval (CI) 0.59-0.67 for PTS. The model's performance 
appeared to be better for the outcomes moderate to severe PTS and severe PTS (c-statistic 
0.67; 95% CI 0.62 to 0.72 for moderate-severe PTS and 0.70; 0.64 to 0.77 for severe PTS). 








We externally validated the SOX-PTS score for estimating the risk of developing PTS, 
moderate to severe PTS, and severe PTS, in patients with proximal DVT. The score may be 
useful to predict PTS at the time of DVT diagnosis. Further external validation in different 
patient cohorts is required.  
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The post-thrombotic syndrome (PTS) is a chronic complication of deep vein thrombosis 
(DVT) that develops in up to 50% of patients despite optimal anticoagulation, usually 
becoming established in the first two years after DVT [1. Manifestations range from mild leg 
pain and discomfort to chronic non-healing leg ulcers. In order to inform patients with DVT 
about their future outcome, improve their management, and optimally design studies of 
preventive and treatment strategies, better prognostication of the individual patient's risk of 
developing PTS is needed.  
 
We recently developed the SOX-PTS score, a clinical prediction model for PTS that was 
derived in a prospective cohort of patients with proximal DVT (SOX Trial participants) [2. 
The score identified 3 independent predictors, namely anatomical extent of DVT (1 point for 
iliac vein involvement); body mass index (BMI) (2 points for BMI ≥35 kg/m2); and baseline 
Villalta score (1 point for ≥10; 2 points for ≥14), with a possible maximum score of 5, that 
were combined into a model that predicted the risk for PTS development. However, this score 
has not been externally validated in an independent sample. The aim of the current study was 
to apply the SOX-PTS score to patients whose data were not used in model development, 




The validation cohort consisted of participants in the Acute Venous Thrombosis: Thrombus 
Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial, a multicenter 
randomized controlled trial of anticoagulation alone (control group) compared with 





prevention of PTS. [3 Patients with symptomatic proximal DVT involving the femoral, 
common femoral or iliac vein (with or without other involved ipsilateral veins) were enrolled 
at 56 clinical centers in the United States (list of participating centers in Supporting 
Information). Patients were excluded if they were younger than 16 or older than 75 years of 
age, were pregnant, had symptoms for more than 14 days, were at high bleeding risk, had 
active cancer, had established PTS, or had ipsilateral DVT in the previous 2 years. All the 
patients provided written informed consent.  
 
Patients in each treatment group received initial and long-term anticoagulant therapy, and 
were provided sized-to-fit, knee-high, elastic compression stockings (30 to 40 mm Hg of 
pressure) at the 10-day follow-up visit and every 6 months. [4  In the PCDT arm, 
recombinant tissue plasminogen activator (rt-PA) was delivered via one of three methods, as 
published previously. [3, 5 
 
Outcome 
The primary outcome of the ATTRACT trial was the development of PTS according to the 
Villalta scale. The Villalta scale is a clinical measure for PTS that grades the severity of 5 
patient-rated symptoms (pain, cramps, heaviness, pruritus, and paresthesia) and 6 clinician-
rated clinical signs (edema, redness, skin induration, hyperpigmentation, venous ectasia, and 
pain on calf compression) from 0 (absent) to 3 (severe). [6  A summative score of 5 or more 
or an ulcer in the leg with the index DVT indicates the presence of the PTS. In ATTRACT, 
these criteria had to be met at any time between the 6-month and the 24-month follow-up 







All available data in the database were used to maximize the power and generalizability of 
the results.  
 
We assessed the predictive performance of the SOX-PTS score in the ATTRACT trial cohort 
by examining measures of discrimination and calibration. Discrimination is the ability of the 
risk score to differentiate between patients who do and do not experience an event during the 
study period. This measure is quantified by calculating the c-statistic, the equivalent of the 
receiver operating characteristic (ROC) based area under the curve, with a value of 0.5 
representing chance and 1 representing perfect discrimination. Calibration refers to how 
closely the predicted 24-month PTS rates using the SOX-PTS score agreed with the observed 
24-month PTS rates. This was assessed by plotting observed proportions versus predicted 
probabilities and by calculating the calibration slope. [7 
 
Because the PTS outcome in the derivation cohort was defined using Ginsberg PTS criteria 
[8, which are known to capture more severe PTS than Villalta PTS criteria [9, we planned a 
pre-specified secondary analysis that assessed model performance with moderate-severe PTS 
(Villalta score of 10-14) and severe PTS (Villalta score>14) as outcomes.  
 
Handling of missing data  
Multiple imputation was performed on patients in the ATTRACT cohort that had missing 
outcome data (Villalta scores) assuming they were missing at random. Patients who missed 
all four PTS assessments were included in the multiple imputation. In addition, missing PTS 
assessments in patients who were lost to follow up before completing all four PTS 
assessments were also imputed if all existing assessments had a Villalta score <5. Villalta 





covariates. We created 20 imputed datasets, with the missing values replaced by imputed 
values drawn from their predicted distribution by using the observed data. Fully conditional 
statement was chosen as the imputation method. In this method, the predictive mean 
matching method is used for all continuous variables and the logistic regression method is 
used for all classification variables. [10  No interaction terms were included in the 
imputation model. Performance of the SOX-PTS score in the imputed ATTRACT dataset 
was analyzed as a sensitivity analysis. The main analysis was performed on the non-imputed 
original dataset.  
 
Exploratory analysis- model updating   
In exploring model updating, we considered the following baseline covariates from the 
ATTRACT cohort: treatment arm, iliofemoral vs. femoral-popliteal DVT, sex, age, BMI, 
DVT symptom duration, previous ipsilateral DVT, contralateral DVT, and inpatient or 
outpatient status at the time of DVT diagnosis. Only statistically significant covariates (P 
<0.05) in a multivariate logistic regression were used to construct a new risk score. The 
discrimination and calibration of the new risk score were examined using the ATTRACT 
data. A sensitivity analysis was conducted on the discrimination and calibration of the new 
risk score using the imputed ATTRACT dataset. The above analyses were repeated for two 
secondary outcomes: moderate to severe PTS, and severe PTS. Internal validation of the new 
score was performed within the ATTRACT database using the bootstrapping technique.  
 
All analyses were performed using SAS statistical software version 9.4 (SAS Institute Inc). 
 
Results  





ATTRACT trial (337 to the PCDT group and 355 to the control group). One patient who was 
assigned to the PCDT group who was found not to have a DVT was excluded from all 
analyses. PTS developed over the 24-month period in 157 of 336 patients (47%) assigned to 
the PCDT group and in 171 of 355 patients (48%) assigned to the control group (risk ratio, 
0.96; 95% confidence interval (CI) 0.82 -1.11). [3 As the intervention had no significant 
effect on the outcome, we addressed both arms of the study as one cohort.  
 
Comparison of baseline characteristics of the SOX and ATTRACT cohorts 
Compared to the SOX cohort, patients in the ATTRACT cohort were younger, had higher 
BMI, and a greater proportion had unprovoked DVT.  None had cancer associated DVT 
(Table 1). Twenty five percent of patients in the ATTRACT cohort had previous DVT at 
baseline compared to none in the SOX cohort. Most patients in the SOX and ATTRACT 
trials were treated with low molecular weight heparin followed by a vitamin K antagonist. 
Patients in the ATTRACT cohort received a longer median duration of anticoagulation.  
 
Another important difference between the two cohorts was how the anatomical extent of 
DVT was categorized. Both trials categorized patients according to the most proximal extent 
of DVT. However, in the ATTRACT trial, DVT was categorized as iliofemoral or femoral-
popliteal, whereas in the SOX trial DVT was categorized as iliac, common femoral, femoral 
or popliteal. Unlike the SOX trial, the ATTRACT trial did not include patients with popliteal 
DVT (i.e., without more proximal involvement). We were not able to divide ATTRACT 
patients with iliofemoral DVT into those with only common femoral involvement and those 
with iliac involvement.  
 





Table 2 shows results of the primary analysis, validation of the SOX-PTS score in the 
ATTRACT trial cohort. The odds ratio for PTS for patients with a SOX-PTS score of 1 (vs 0) 
in the ATTRACT cohort was 1.43 (95% CI 0.92 to 2.23), whereas in the SOX cohort it was 
2.29 (1.27 to 4.11). The odds for PTS development increased to 4.52 (2.59 to 8.06) for 
patients in the ATTRACT cohort who had a SOX –PTS score of ≥4 (vs. 0) compared to 5.90 
(2.09 to 16.62) in the SOX cohort. Within the ATTRACT cohort, 69% of patients who had a 
SOX-PTS score ≥4 developed PTS, vs. 42% of patients who had a score of 1 (Table 2).  
When applied to the ATTRACT population, the SOX-PTS score achieved good 
discrimination (c-statistic 0.63; 95% CI 0.59-0.67) and calibration (Figure 1). 
 
Secondary analyses 
Results of the secondary analysis using moderate-severe PTS (Villalta scale≥10) and severe 
PTS (Villalta scale>14) as the outcomes are shown in Table 3 and Figure 1. The model’s 
performance (discrimination and calibration) improved for both secondary outcomes (c-
statistic 0.67; 95% CI 0.62 to 0.72 for moderate-severe PTS and 0.70; 0.64 to 0.77 for severe 
PTS; Table 4).  
 
Distributions of the SOX-PTS score in the SOX and ATTRACT cohorts for the primary and 
secondary outcomes are shown in Table 5. The ATTRACT cohort had more patients 
classified in the higher risk groups according to the SOX-PTS score (score 3 or higher). 
Interestingly, distribution of the scores in the validation cohort was closest to the distribution 
in the derivation cohort when considering moderate-severe PTS as the outcome, probably due 
to the above mentioned differences in definition of the PTS outcome in the two studies (i.e. 






Sensitivity analyses after multiple imputation to replace missing Villalta scores in the 
ATTRACT cohort 
Results of the sensitivity analysis using multiple imputation for patients missing outcome 
data are shown in Table 1S Supporting information. Multiple imputation was performed on 
170 patients, of whom 80 patients missed all four preplanned outcome assessments visits and 
90 patients missed one to three outcome assessment visits. Imputation yielded 95 additional 
patients with PTS than the original dataset.   
 
Distribution of the SOX-PTS score in the SOX trial cohort and imputed ATTRACT trial 
datasets is shown in Table 2S Supporting information. Similarly to results in the non-imputed 
dataset, distribution was closest to that of the derivation (SOX trial) cohort when considering 
moderate to severe PTS as the outcome. Application of the SOX-PTS score on the imputed 
ATTRACT dataset had little effect on the performance of the model (Table 3S of Supporting 
information).  
 
Exploratory analysis- Model updating 
We tried to improve the SOX-PTS model's performance by updating our model. 
Multivariable logistic analysis of the ATTRACT data (using the non-imputed original 
dataset) suggested that advancing age is a predictor of PTS (Table 4S Supporting 
information). Hence, we updated the model by adding age as an additional variable (Table 
5S), categorized into three groups: <40, 40-64, ≥65 years. The updated model has possible 
scores from 1 to 7. Table 6S Supporting information shows the distribution of the updated 
SOX-PTS model in the ATTRACT Study cohort. We repeated secondary analyses with 
moderate-severe PTS and severe PTS as the outcomes (Table 5S). For both the primary 





the original score (for the primary analysis, outcome PTS, c-statistic 0.65; 95% CI 0.61 to 
0.69, for the secondary analyses, outcome moderate-severe PTS, 0.68; 0.63 to 0.72 and 
outcome severe PTS, 0.70; 0.64 to 0.76) (Table 7S). Calibration plots for the updated model 
are presented in Figure 1S supporting information. Internal validation by the bootstrapping 
technique for the updated model is shown in Table 8S Supporting information. Results show 
good agreement with the observed estimates. Sensitivity analysis after multiple imputation 
for patients with missing outcome data in the ATTRACT cohort was also performed for the 
updated model (Tables 9S-11S Supporting information). As in the original model, multiple 
imputation had little effect on the performance of the model.    
   
Discussion 
We externally validated the SOX-PTS score in an independent prospective cohort of patients 
with proximal DVT. The model's performance was good, despite differences in 
characteristics between the derivation and validation cohorts.  
 
In terms of these differences, first, patients in the ATTRACT cohort might have had a higher 
baseline risk for PTS (25% of the cohort had recurrent DVT, more patients were in the higher 
BMI categories; both of these factors are known risk factors for PTS). [11, 12 Second, in the 
ATTRACT trial, DVT was categorized into iliofemoral vs femoral-popliteal, whereas in the 
SOX trial, most proximal extent of DVT was divided into four categories (iliac, common 
femoral, femoral and popliteal), hence we were able to pick out iliac DVT, which proved to 
be an important predictor of PTS. [2  Unfortunately, we did not have information on the 
proportions of patients with iliac DVT in the ATTRACT cohort. Nevertheless, we chose not 
to remove this predictor from the score, as we believe that other groups will try to validate the 





categories of extent of DVT, like the SOX cohort did). If we removed this predictor, the 
opportunity to look at the performance of what is considered to be an important predictor of 
PTS, in other populations, would have been lost. Third, outcome definition was also different 
between the two cohorts: in the derivation cohort (SOX cohort), Ginsberg's criteria were used 
to define PTS, whereas in the validation cohort (ATTRACT cohort), the Villalta scale was 
used. Ginsberg-defined PTS captures more severe PTS than Villalta-defined PTS. [9 To 
overcome this issue, we preplanned a secondary analysis looking at moderate-severe and 
severe PTS according to the Villalta scale as the outcomes in the ATTRACT cohort. Indeed, 
the model's performance was better when these secondary outcomes were considered.  
 
One additional difference between the derivation and validation cohorts should be 
considered. The experimental interventions that the study participants in the two cohorts 
received were different (active elastic compression stockings in the SOX trial and PCDT in 
the ATTRACT trial) and might have modified the likelihood of developing PTS. However, 
during ATTRACT trial follow up, there was no significant between-group difference in the 
percentage of patients who developed PTS (47% in the PCDT group and 48% in the control 
group; risk ratio, 0.96; 95% CI, 0.82 to 1.11). Therefore, we analyzed both arms of the study 
as one combined cohort. We also accounted for this fact by including assigned treatment arm 
as a parameter in the multivariable analysis, and it did not influence the final model.  
 
To the best of our knowledge, only two other prediction models for PTS have been published. 
[13, 14 The model by Amin and colleagues is [13 a two-step model consisting of a first 
model to be applied at baseline to predict the probability of developing PTS at 6 months, and 
a second model to be applied at 6 months to predict the probability of PTS at 24 months for 





were: age>56, BMI>30, male sex, varicose veins, history of venous thrombosis, smoking 
status, provoked DVT and iliofemoral DVT. Predictor variables in the second step were the 
same as in the first step with the addition of residual vein obstruction. The model by Méan 
and colleagues [14 includes age > 75 years, prior varicose vein surgery, multi-level 
thrombosis, concomitant use of antiplatelet/ non-steroidal anti-inflammatory drugs, and 
number of leg symptoms and signs. We could not validate these two prediction models in the 
ATTRACT cohort because of lack of data on some predictor variables (smoking status, 
varicose veins and residual obstruction for the prediction model by Amin et al [13, and prior 
varicose vein surgery for the prediction model by Méan et al [14). However, the three 
models are in agreement regarding some of the predictor variables (e.g., age, iliofemoral 
involvement in DVT, severe symptoms and signs at DVT diagnosis). A comparative 
validation study evaluating the performance of different PTS prediction models on the same 
data set would generate additional important information.  
 
The present study has potential limitations. In addition to differences between the two cohorts 
as elaborated above, this validation cohort (like the derivation cohort) is based on data from a 
randomized trial and not a prospective cohort study designed specifically for this purpose. 
However, we controlled for this by including the treatment arm as a parameter in the 
multivariable analysis, and it did not influence the final model. Also, as most patients in the 
SOX and ATTRACT trials were treated with low molecular heparin followed by warfarin, 
the validity of this model in patients treated with the newer direct oral anticoagulants should 
be addressed.  
 
In conclusion, we externally validated the SOX-PTS score for estimating the risk of 





All items in the model are readily available at the time of DVT diagnosis and thus the score 
may be useful to estimate the risk of developing PTS at the time of DVT diagnosis. Further 
external validation in different patient cohorts is required.  
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Table 1: Baseline Characteristics of the SOX trial and ATTRACT trial participants  
Characteristics 
SOX  
n = 762 
ATTRACT 
 n = 691 
p-value 
Sex - female: n (%) 305 (40) 265 (38) 0.51 
Age Category (years): n (%)   < 0.001 
< 40 129 (17) 152 (22)  
40-64 423 (56) 418 (60)  
≥ 65 210 (28) 121 (18)  
Ethnicity: n (%)   < 0.001 
Caucasian 688 (90) 542 (78)  
Other 74 (10) 149 (22)  
Iliac DVT - yes: n (%) 90 (12) NA NA 
Common femoral vein or Iliac vein DVT - 
yes: n (%) 
NA 391 (57) NA 
Baseline Villalta Score category    0.002 
0-4 (none) 164 (22) 126 (18)  
5-9 (mild) 298 (39) 239 (35)  
10-14 (moderate) 216 (28) 192 (18)  
>14 (severe) 84 (11) 132 (19)  
Unknown 0 2 (<1)  
DVT Type: n (%)   < 0.001 
Cancer associated 79 (10) 0  
Secondary Risk Factors 206 (27) 101 (15)  
Unprovoked 477 (63) 590 (85)  
Side of DVT: n (%)   0.018 
Left 422 (55) 425 (62)  
Right 340 (45) 266 (38)  
Previous DVT or PE: n (%) 0 170 (25) < 0.001 
BMI category (kg/m2): n (%)   < 0.001 
< 25 193 (25) 115 (17)  
25-34 457 (60) 388 (57)  
≥ 35 112 (15) 184 (27)  
Unknown 0 4 (1)  
Duration of anticoagulation (days): median 
(Q1, Q3) 
185 (111-233) 223 (186, 372) < 0.001* 
PTS; post thrombotic syndrome, DVT; deep vein thrombosis, BMI; body mass index  






Table 2: Performance of SOX-PTS score in SOX Trial (derivation set) and ATTRACT 




(N = 762) 
ATTRACT Study 









More extensive (vs less extensive) 
DVT*, 1 point 
 1.96 
(1.08 to 3.57) 
 
1.14 
(0.83 to 1.55) 
BMI ≥ 35 (vs < 35), 2 points 
 2.17 
(1.27 to 3.72) 
 
1.94 
(1.37 to 2.78) 
Baseline Villalta score category# 
(vs None to Mild) 
 
   
Severe,  2 points  
2.64 
(1.41 to 4.96) 
86/132 (65) 
2.60 
(1.71 to 4.00) 
Moderate, 1 point  
2.00 
(1.21 to 3.29) 
98/192 (51) 
1.49 
(1.04 to 2.14) 
None to Mild  n/a 144/367 (39) n/a 
SOX-PTS Score (vs 0)     
≥ 4  6/21 (29) 
5.90 
(2.09 to 16.62) 
61/88 (69) 
4.52 
(2.59 to 8.06) 
3  14/56 (25) 
4.91 
(2.35 to 10.27) 
74/120 (62) 
3.22 
(1.96 to 5.34) 
2  20/122 (16) 
2.89 
(1.53 to 5.47) 
61/136 (45) 
1.63 
(1.01 to 2.63) 
1  27/201 (13) 
2.29 
(1.27 to 4.11) 
82/197 (42) 
1.43 
(0.92 to 2.23) 
0 23/362 (  6) n/a 50/150 (33) n/a 
PTS; post thrombotic syndrome, DVT; deep vein thrombosis, BMI; body mass index OR; odds ratio. 
*Iliac vs non iliac vein involvement in the SOX trial; Common femoral and/or iliac vein vs femoral-popliteal 
vein involvement in the ATTRACT trial 











Table 3: Secondary analyses: Performance of SOX-PTS score using moderate-severe 
PTS and severe PTS as the outcomes 
Category 
ATTRACT  
Moderate to Severe PTS 
ATTRACT  
Severe PTS 
OR for PTS 
(95% CI) 
OR for PTS  
(95% CI) 
More extensive (vs. less 
extensive) DVT* 
1.25 
(0.84 to 1.87) 
1.31 
(0.76 to 2.26) 
BMI ≥ 35 (vs < 35) 
1.61 
(1.07 to 2.41) 
2.03 
(1.20 to 3.43) 
Baseline Villalta score category# 









(2.61 to 6.77) 
2.16 





(2.48 to 8.51) 
1.70 
(0.88 to 3.30) 
SOX-PTS Score (vs 0)  
6.72 
(4.42 to 13.86) 
4.33 
(2.26 to 8.74) 
2.30 
(1.16 to 4.72) 
1.81 
(0.94 to 3.65) 
 
12.17 
(4.03 to 36.71) 
6.87 
(2.27 to 20.79) 
3.53 
(1.11 to 11.23) 
2.58 








PTS; post thrombotic syndrome, DVT; deep vein thrombosis, BMI; body mass index OR; odds ratio 
*Iliac vs non iliac vein involvement in the SOX trial; Common femoral and/or iliac vein vs femoral-popliteal 
vein involvement in the ATTRACT trial 







































% Concordant* 58.0 53.1 63.6 57.3 67.3 61.4 
% Discordant 30.0 26.7 26.6 23.8 23.9 20.6 
% Tied 12.0 20.2 9.8 18.9 8.8 18.0 
Somers’ D 0.28 0.27 0.37 0.34 0.43 0.41 
Gamma 0.32 0.33 0.41 0.41 0.48 0.50 




(0.60 to 0.68) 
0.63 
(0.59 to 0.67) 
0.69 
(0.64 to 0.73) 
0.67 
(0.62 to 0.72) 
0.72 
(0.65 to 0.78) 
0.70 
(0.64 to 0.77) 
 
*To evaluate concordance, all possible pairs of patients (i.e. one patient has a PTS event and the other has no PTS event) are assessed. For a pair of patients, the actual 
outcome (i.e. PTS) and the predicted probability of outcome from the logistic model can have 3 types of results: 
1) Concordant: in the pair, the patient with higher predicted probability had PTS event  
2) Discordant: in the pair, the patient with lower predicted probability had PTS event 


















(N = 762) 
ATTRACT 
(N = 691) 
PTS*  
 N (%) 
PTS#  
 N (%) 
Moderate-Severe 
PTS#  N (%) 
Severe PTS#  
N (%) 
0 23/362 ( 6) 50/150 (33) 14/150 ( 9) 4/150 ( 3) 
1 27/201 (13) 82/197 (42) 31/197 (16) 13/197 ( 7) 
2 20/122 (16) 61/136 (45) 26/136 (19) 12/136 ( 9) 
3 14/56 (25) 74/120 (62) 37/120 (31) 19/120 (16) 
4 6/20 (30) 38/54 (70) 22/54 (41) 14/54 (26) 
5 0/1 23/34 (68) 14/34 (41) 8/34 (24) 
PTS; post thrombotic syndrome 
* PTS was defined according to the Ginsberg criteria 






















Figure 1. Calibration plots for the SOX-PTS score applied to the ATTRACT cohort 
A. PTS as outcome 
B. Moderate-severe PTS as outcome 













Supporting materials for “External validation of the SOX-PTS score (clinical prediction 
model for the post-thrombotic syndrome) in a prospective multicenter trial of patients with 
proximal deep vein thrombosis” 
 
 
ATTRACT Clinical Centers 
Adventist Midwest Health  
Albert Einstein Medical Center  
Allegheny General Hospital  
Ann Arbor VA Health Center  
Baptist Cardiac and Vascular Institute 
Central DuPage Hospital  
Christiana Care Hospital  
Cleveland Clinic Foundation  
Danbury Hospital 
Eastern Connecticut Hematology & Oncology Associates  
Florida Hospital  
Forsyth Medical Center  
Gundersen Clinic, Ltd  
Georgetown University  
Henry Ford Health System  
Holy Name Medical Center 
Jobst Vascular Center 
Maine Medical Center 
Massachusetts General Hospital  
Mayo Clinic  
Mease Countyside Hospital  
Medical College of Wisconsin/Froedtert Hospital & Clinics  
Medical University of South Carolina  
Oregon Health & Science University 
Pepin Heart Hospital and Dr. Kiran C. Patel Research Institute  
Phoenix Heart & Cardiovascular 
Riverside Methodist Hospital 
Rhode Island Hospital  
Providence Sacred Heart Medical Center & Children’s Hospital 
Southern Illinois University  
St. Elizabeth Regional Medical Center (NE) 
St. Joseph Hospital  
St. Luke’s Hospital and Health Network 
St. Luke’s Hospital: Brandt Wible  





Stanford University Medical Center 
Staten Island University Hospital 
Temple University Hospital 
The Reading Hospital 
TriHealth/Good Samaritan Hospital 
University of Iowa 
University of Illinois- Chicago  
University of Maryland 
University of Michigan Hospitals and Health Centers 
University of Minnesota  
University of New Mexico  
University of North Carolina 
University of Pittsburgh  
University of Utah Medical Center  
University of Virginia Health System  
Utah Valley Reginal Medical Center  
Weill Cornell Medical College  
Western Penn Allegheny Health System  





































Severe PTS  
OR for PTS 
(95% CI) 
OR for PTS  
(95% CI) 
OR for PTS  
(95% CI) 
More extensive DVT*(vs less 
extensive) 
1.15 
(0.80 to 1.66) 
1.19 
(0.81 to 1.73) 
1.30 
(0.77 to 2.21) 
BMI ≥ 35 (vs < 35) 
1.77 
(1.13 to 2.77) 
1.35 
(0.89 to 2.05) 
1.65 
(1.00 to 2.74) 
Baseline Villalta score category# 










(1.17 to 2.71) 
5.06 
(2.93 to 8.73) 
5.72 
(2.96 to 11.05) 
Moderate 3.78 
(2.17 to 6.59) 
2.22 
(1.41 to 3.52) 
2.00 
(1.02 to 3.91) 
SOX-PTS Score (vs 0)    
≥ 4 
5.54 
(2.74 to 11.18) 
6.01 
(2.85 to 12.65) 
10.38 
(3.29 to 32.76) 
         3 
3.33 
(1.86 to 5.96) 
4.15 
(2.11 to 8.18) 
6.09 
(1.97 to 18.79) 
        2 
1.74 
(1.04 to 2.91) 
2.38 
(1.18 to 4.78) 
3.30 
(1.03 to 10.56) 
1 
1.48 
(0.92 to 2.36) 
1.92 
(1.01 to 3.63) 
2.42 
(0.79 to 7.43) 
Note: ATTRACT results are based on 20 multiple imputation datasets 
PTS; post thrombotic syndrome, DVT; deep vein thrombosis, BMI; body mass index OR; odds 
ratio. 
* Iliac vs non iliac vein involvement in the SOX trial; Common femoral and/or iliac vein vs 
femoral-popliteal vein involvement in the ATTRACT trial 

















Table 2S: Distribution of the SOX-PTS Score in the SOX trial cohort and imputed 







(N = 762) 
ATTRACT, multiple imputation 
(N = 691) 
PTS 




PTS  N (%) 
Severe PTS#  
 N (%) 
0 23/362 ( 6) 69.4/150 (45) 22.5/150 (15) 7.9/150 ( 5) 
1 27/201 (13) 110.3/197 (56) 49.5/197 (25) 22.4/197 (11) 
2 20/122 (16) 81.5 /136 (60) 40.0/136 (29) 20.3/136 (15) 
3 14/56 (25) 89/120 (74) 50.5/120 (42) 29.2/120 (24) 
4 6/20 (30) 41.6/54 (77) 24.1/54 (45) 17.3/54 (32) 
5 0/1 31.2/34 (92) 21.0/34 (62) 13.8/34 (41) 
PTS; post thrombotic syndrome 
* PTS was defined according to the Ginsberg criteria 
# PTS was defined according to Villalta score categories: None, score of 0-4; Mild, 5-9; 






































PTS as Outcome Moderate-Severe 
PTS as Outcome 
Severe PTS as 
Outcome 
% Concordant 53.5 (50.9 to 55.5 )  55.8 (52.8 to 59.8) 60.0 (55.7 to 64.2) 
% Discordant 25.8 (24.1 to 28.1)  24.9 (21.6 to 27.4) 21.7 (18.3 to 25.3) 
% Tied 20.7 (20.4 to 21.0)  19.4 (18.6 to 19.9) 18.3 (17.5 to 19.0) 
Somers’ D 0.28 (0.23 to 0.31)   0.31 (0.25 to 0.38) 0.38 (0.30 to 0.46) 
Gamma 0.35 (0.29 to 0.39)  0.38 (0.32 to 0.47) 0.47 (0.37 to 0.56) 
Tau-a 0.13 (0.11 to 0.15)   0.13 (0.11 to 0.16) 0.10 (0.09 to 0.13) 







































Table 4S: Multivariable logistic regression model of the association between ATTRACT 
population baseline characteristics and PTS development 
Baseline Variables OR (95% CI) P-value 
Treatment arm (PCDT vs. No PCDT) 0.91 (0.65, 1.27) 0.57 
Iliofemoral vs. Popliteal DVT  1.17 (0.82, 1.68) 0.39 
Clinical Centre   0.0008 
Age (per year) 1.03 (1.01, 1.04) <0.0001 
Sex (Female vs. Male) 0.70 (0.49, 1.01) 0.060 
BMI, kg/m2 (per unit increase) 1.05 (1.02, 1.07) 0.0003 
DVT Symptom Duration (per day) 1.04 (1.00, 1.09) 0.064 
Ipsilateral DVT (No vs. Yes) 1.02 (0.19, 5.51) 0.77 
Contralateral DVT (No vs. Yes) 1.06 (0.49, 2.31) 0.17 
Inpatient (No vs. Yes) 1.06 (0.65, 1.75) 0.81 
Baseline Villalta Score (per point increase)  1.13 (1.09, 1.17) <0.0001 





















Table 5S: Updated SOX-PTS score including age as an additional variable applied to the 
ATTRACT cohort 
 
Parameter PTS  Moderate-Severe PTS Severe  PTS  Points 
OR (95%CI) OR (95%CI) OR (95%CI) 
More extensive (vs less 
extensive) DVT* 
1.17 (0.85 to 1.61) 1.30 (0.87 to 1.95) 1.36 (0.78 to 2.36) 1 
BMI ≥ 35 (vs < 35) 2.03 (1.42 to 2.91)  1.67 (1.10 to 2.53) 2.04 (1.20 to 3.47) 2 
Baseline Villalta score 
category# (vs None to 
Mild) 
    
     Severe 2.66 (1.73 to 4.11) 4.11 (2.52 to 6.71) 4.34 (2.32 to 8.13) 2 
     Moderate 1.59 (1.10 to 2.30) 2.26 (1.42 to 3.59) 1.71 (0.88 to3.32) 1 
Age Category (vs < 40)     
      ≥ 65 2.37 (1.42 to 3.95) 2.20 (1.11 to 4.37) 1.28 (0.48 to 3.40) 2 
      40-64 1.90 (1.27 to 2.83) 2.23 (1.30 to 3.83) 1.83 (0.91 to 3.69) 1 
Intercept -0.73 (-1.02 to- 0.43) -2.90 ( -3.53 to -2.27) -3.63 (-4.48 to -2.78)  
Updated SOX-PTS 
score (vs 0)  
    
≥ 6 13.22 (3.76 to 46.53) 6.86 (1.71 to 27.58) 10.02 (3.01 to 33.29)  
5 9.93 (3.27 to 30.11) 5.56 (1.51 to 20.47) 6.47 (2.14 to 19.53)  
4 7.47 (2.63 to 21.24) 3.99 (1.13 to 14.14) 7.20 (2.62 to 19.80)  
3 4.66 (1.69 to12.88) 2.00 (0.57 to 7.07) 2.86 (1.00 to 8.15)  
2 2.78 (1.01 to 7.64) 1.43 (0.41 to 5.06) 1.76 (0.60 to5.18)  
1 2.63 (0.93 to7.40) 0.83 (0.22 to 3.21) NA§  
PTS; post thrombotic syndrome, DVT; deep vein thrombosis, BMI; body mass index OR; odds ratio 
*Iliac vs non iliac vein involvement in the SOX trial; Common femoral and/or iliac vein vs femoral-
popliteal vein involvement in the ATTRACT trial 
#Villalta score categories: None, score of 0-4; Mild, 5-9; Moderate, 10-14; Severe, >14 
















(N = 691) 
PTS  
 N (%) 
Moderate-Severe PTS 
N (%) 
Severe PTS  
 N (%) 
0 5/28 (18)  3/28 (11) 0/28 (0) 
1 44/121 (36)  11/121 (9) 5/121 (4) 
2 72/191 (38)  28/191 (15) 11/191 (6) 
3 78/155 (50)  30/155 (19) 14/155 (9) 
4 65/105 (62)  34/105 (32) 21/105 (20) 
5 41/60 (68)  24/60 (40) 11/60 (18) 
6 21/29 (72)  12/29 (41) 7/29 (24) 
7 2/2 (100)  2/2 (100) 1/2 (50) 
 



































Table 7S: Model Fit Statistics and Association of Predicted Probability and Observed 










PTS as outcome 




















%Concordant 63.3 55.8 66.3 59.3 70.2 61.7 
%Discordant 31.5 26.0 27.7 24.1 25.6 21.8 
% Tied 5.2 18.2 6.0 16.7 4.2 16.5 
Somers’ D 0.32 0.30 0.39 0.35 0.45 0.40 
Gamma 0.34 0.37 0.41 0.42 0.47 0.48 




(0.62 to 0.70) 
0.65  
(0.61 to 0.69) 
0.70  
(0.65 to 0.75) 
0.68  
(0.63 to 0.72) 
0.73  
(0.66 to 0.79) 
0.70  
(0.64 to 0.76) 






























Table 8S: Internal Validation with Bootstrapping Technique of updated* SOX-PTS score- 








PTS Moderate-Severe PTS Severe PTS§ 




































































































































C Statistics for Bootstrap Samples, Updated SOX-PTS Score 
Data C-Statistics (95% CI) 
ATTRACT – PTS (Continuous)  0.65 (0.61 to 0.69) 
ATTRACT – Moderate-Severe PTS (Continuous)  0.68 (0.63 to 0.73) 
ATTRACT – Severe PTS (Continuous)  0.70 (0.64 to 0.76) 
ATTRACT – PTS (Categorical)  0.64 (0.60 to 0.68) 
ATTRACT – Moderate-Severe PTS (Categorical)  0.66 (0.62 to 0.71) 
ATTRACT – Severe PTS (Categorical)  0.68 (0.62 to 0.74) 
*Updated model includes age as an additional variable 
#Boot = bootstrap estimate;  















Severe PTS  
OR for PTS 
(95% CI) 
OR for PTS  
(95% CI) 
OR for PTS  
(95% CI) 
More extensive (vs less extensive) 
DVT* 
1.19 
(0.82 to 1.72) 
1.23 
(0.84 to 1.79) 
1.34 
(0.78 to 2.29) 
BMI ≥ 35 (vs < 35) 
1.82 
(1.15 to 2.86) 
1.36 
(0.89 to 2.08) 
1.67 
(1.00 to 2.79) 
Age (vs. < 40)    
≥ 65 
3.82 
(2.17 to 6.71) 
4.88 
(2.81 to 8.50) 
5.41 
(2.80 to 10.45) 
40-64 
1.85 
(1.21 to 2.83) 
2.25 
(1.41 to 3.59) 
1.99 
(1.01 to 3.93) 
Baseline Villalta score category# 
(vs None to Mild) 




(0.94 to 2.96) 
1.24 
(0.63 to 2.45) 
0.91 
(0.35 to 2.33) 
Moderate 
1.54 
(0.98 to 2.40) 
1.52 
(0.90 to 2.58) 
1.31 
(0.62 to 2.75) 





(2.42 to 67.00) 
6.44 
(1.40 to 29.73) 
7.71 
(2.21 to 26.90) 
          5 
5.56 
(1.71 to 18.05) 
4.52 
(1.07 to 19.00) 
5.35  
(1.87 to 15.32) 
         4 
4.22 
(1.35 to 13.13) 
3.55 
(0.91 to 13.81) 
5.62 
(2.04 to 15.52) 
3 
2.43 
(0.84 to 7.02) 
1.91 
(0.47 to 7.78) 
2.47 
(0.89 to 6.87) 
2 
1.53 
(0.55 to 4.24) 
1.51 
(0.40 to 5.68) 
1.55 
(0.59 to 4.04) 
1 
1.37 
(0.47 to 4.01) 
0.94 
(0.24 to 3.64) 
 
Note: ATTRACT results are based on 20 multiple imputation datasets 
*Updated model includes age as an additional variable 













(N = 691) 
PTS / N (%) 
Moderate-Severe PTS 
/ N (%) 
Severe PTS / N (%) 
0 11.7/28 (42) 5.1/28 (18) 0.9/28 (3) 
1 59.5/121 (49) 20.1/121 (17) 9.4/121 (8) 
2 99.3/191 (52) 46/191 (24) 19.3/191 (10) 
3 98.1/155 (63) 44.4/155 (29) 23.4/155 (15) 
4 78.6/105 (75) 44.9/105 (43) 30.2/105 (29) 
5 47.8/60 (80) 29.2/60 (49) 16.7/60 (28) 
6 25.9/29 (89) 15.8/29 (54) 10.1/29 (35) 
7 2/2 (100) 2/2 (100) 1/2 (50) 
Note: ATTRACT results are based on 20 multiple imputation datasets 




















Table 11S: Model Fit Statistics for updated* SOX-PTS Score, after multiple imputation  
Model Fit Statistics 
PTS Moderate-Severe PTS Severe PTS 
Mean Min, Max Mean Min, Max Mean Min, Max 
%Concordant  55.1 50.8, 57.8 56.2 53.2, 59.9 59.5 55.5, 65.0 
%Discordant  25.7 20.6, 28.5 26.0 23.1, 28.5 23.3 19.0, 26.7 
% Tied 19.2 18.4, 28.6 17.8 16.9, 19.7 17.2 16.0, 19.3 
Somers’ D 0.29 0.24, 0.34 0.30 0.25, 0.37 0.36 0.29, 0.46 
Gamma 0.36 0.30, 0.42 0.37 0.30, 0.44 0.44 0.35, 0.55 
Tau-a 0.14 0.11, 0.16 0.13 0.11, 0.15 0.10 0.08, 0.12 
c-statistic (95%CI) 
continuous  
0.65 (0.60 to 0.69) 
 
0.65 (0.59 to 0.70) 
 
0.68 (0.61 to 0.74) 
c-statistic (95%CI) 
categorical 
0.65 (0.60 to 0.69) 
 
0.65 (0.60 to 0.70) 
 
0.68 (0.61 to 0.75) 




































Figure 1S. Calibration plots for updated* SOX-PTS score applied to the ATTRACT cohort 
 
A. PTS as outcome 
 
B. Moderate- severe PTS as outcome 
 
C. Severe PTS as outcome 
 
*Updated model includes age as an additional variable 
 
 
 
 
 
 
 
 
 
